IZN-101 is a novel new treatment in development for Ankylosing Spondylitis (AS), a chronic, incurable, and progressive type of arthritis that affects the spine and can lead to significant disability and reduced quality of life. Our Phase II study aims to demonstrate the efficacy of IZN-101 in reduci...See more
Headquarters:
United Kingdom of Great Britain and Northern Ireland
Company Type:
SME
Company size:
1-10 Employees
Address:
OXFORD, GB
LOW
spending power
